China’s WuXi, Johnson & Johnson-backed XW Labs lands $17.5M series B

The biotech is focused on mitochondria in relation to certain CNS disorders

Chinese neurological disorders startup XW Laboratories has seen a $17.5 million series B, bumping up its total raise from its first round to $23 million.

The funding boost was led by Elements Capital and WI Harper, with help from new investor KTB Network, and all existing investors Kleiner Perkins Caufield & Byers China (KPCB China), Johnson & Johnson Innovation, and WuXi Venture.

XW Labs said in a statement that it will “utilize funds to continue the development of its multiple programs that are entering clinical and IND-enabling studies.”


Like this story? Subscribe to FierceBiotech!

Biopharma is a fast-growing world where big ideas come along every day. Our subscribers rely on FierceBiotech as their must-read source for the latest news, analysis and data in the world of biotech and pharma R&D. Sign up today to get biotech news and updates delivered to your inbox and read on the go.

It focuses on several areas: The first is targeting a boost to the safety profiles of existing meds, as well as potential new indications.

The other is a new platform focused on reducing damage to the mitochondria, the so-called “powerhouses of the cell,” which has been linked to a number of neurological disorders.

RELATED: Boosting a mitochondria-targeting protein could postpone aging

“Our company is entering a critical stage where we anticipate at least one program to enter clinical trials per year starting in 2018,” said Jia-Ning Xiang, founder and CEO of XW Labs.

More details on specific targets and MAOs were not given.

Suggested Articles

Avidity Biosciences is on a roll—after inking an R&D deal with Eli Lilly and hiring a new CEO, the company is reeling in $100 million.

What the NASH field needs, says Genfit CEO Pascal Prigent, is something like the Hb1Ac test for diabetes.

Dubbed “Project Nightingale,” the efforts were announced amid concerns and federal inquiries into the data’s safekeeping and patient consent for use.